UBS GLOBAL ASSET MANAGEMENT AMERICAS INC 13D and 13G filings for Prelude Therapeutics Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 1:49 pm Sale |
2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC | 12,265,852 5.421% |
-4,296,594 (-25.94%) |
Filing |
| 2024-02-13 1:34 pm Sale |
2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC | 0 0.000% |
-2,507,992 (Position Closed) |
Filing |
| 2023-02-13 10:52 am Purchase |
2022-12-30 | 13G | Prelude Therapeutics Incorporated PRLD |
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC | 2,507,992 5.240% |
2,507,992 (New Position) |
Filing |
| 2023-02-13 10:49 am Purchase |
2022-12-30 | 13G | Prelude Therapeutics Incorporated PRLD |
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC | 16,562,446 6.620% |
16,562,446 (New Position) |
Filing |